This course has expired. View available courses.
Endocrinology, Medication Management
GLP-1 receptor agonists and CV risk: what do GPs need to know?
While the majority of people with type 2 diabetes (T2D) do not have established cardiovascular disease (CVD), most are at risk for a cardiovascular (CV) event. In recognition of this significant risk, international and local guidelines recommend that the focus of T2D management move beyond glycaemic control to include comprehensive CV risk management. According to […]
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
2
ACCREDITATION
RACGP CPD Program
EXPIRY DATE
2022-09-07
While the majority of people with type 2 diabetes (T2D) do not have established cardiovascular disease (CVD), most are at risk for a cardiovascular (CV) event. In recognition of this significant risk, international and local guidelines recommend that the focus of T2D management move beyond glycaemic control to include comprehensive CV risk management. According to these guidelines, GLP-1 receptor agonists indicated for cardioprotection should now be considered in patients with T2D and established CV disease or in those without established CVD but with multiple CV risk factors.
This 1-hour RACGP accredited activity aims to enable GPs to confidently select patients with T2D who might benefit from initiation of a GLP-1 receptor agonist as first injectable therapy.
This program is supported by an independent educational grant provided from Eli Lilly.
Faculty
Anita Sharma, GP (QLD)
Tom Dover, Endocrinologist (QLD)
Peter Purnell, Cardiologist (WA)
Learning objectives
On completion of this program, GPs will be better able to:
- Recall the latest clinical data on the CV benefits of specific GLP-1 receptor agonists
- Describe how the latest clinical data has impacted management recommendations for patients with T2D who are uncontrolled on metformin
- Re-evaluate existing patients and treatment plans to identify those who might benefit from initiation of a GLP-1 receptor agonist that is indicated for CV benefit
- Confidently initiate a GLP-1 receptor agonist and develop strategies for ensuring optimal outcomes
Accreditation
This Active Learning Module has been approved by RACGP CPD Program for 2 CPD points.
Activity no. 267720
Members are able to claim CPD activity points for 2 points through 'Quick log' on their RACGP CPD Dashboard.